DJIA 16,102.38 -272.38 -1.66%
NASDAQ 4,683.92 -49.58 -1.05%
S&P 500 1,921.22 -29.91 -1.53%
market minute promo

Exelixis (NASDAQ: EXEL)

company name or ticker

We Believe Healthcare's Next Biotech Buyout Target Is…

Which biotech company will be the next buyout target? To answer this question, we turned to three of our healthcare contributors, and this is what they had to say.

Exelixis Up on Swiss Approval of Advanced Melanoma Drug

Why Switzerland Approval Of Exelixis And Roche Drug Combination For Melanoma Is A Big Deal

Exelixis (EXEL) Stock Climbs as Melanoma Treatment Gets Swiss Regulatory Approval

Here's Why Exelixis' Stock Briefly Gained 10% Today

Swiss regulatory approval for Exelixis' experimental skin cancer treatment drove the biotech's shares higher today.

Morning Market Gainers

Benzinga's Top #PreMarket Gainers

Exelixis' Cancer Drug Gets Breakthrough Therapy Status

Benzinga's Top #PreMarket Gainers

'Mad Money' Lightning Round: I'm Staying Away From Alibaba

See More Articles...